266 related articles for article (PubMed ID: 37365612)
1. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
2. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Ueno M; Miyagawa I; Aritomi T; Kimura K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Jun; 24(1):159. PubMed ID: 35768825
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
5. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
Duran E; Bostan OC; Bilgin E; Kaya SB; Bolek EC; Ozer S; Damadoğlu E; Bilgen SA; Karakaya G; Karadag O
Intern Emerg Med; 2022 Apr; 17(3):743-751. PubMed ID: 34628561
[TBL] [Abstract][Full Text] [Related]
6. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
[TBL] [Abstract][Full Text] [Related]
8. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
10. A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab.
Ueno M; Miyagawa I; Kawabe A; Kusaka K; Nakayamada S; Tanaka Y
Mod Rheumatol Case Rep; 2022 Jun; 6(2):243-247. PubMed ID: 35366318
[TBL] [Abstract][Full Text] [Related]
11. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
Ueno M; Miyagawa I; Nakano K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Kawabe A; Yoshinari H; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2021 Mar; 23(1):86. PubMed ID: 33726827
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
Teixeira V; Mohammad AJ; Jones RB; Smith R; Jayne D
RMD Open; 2019; 5(1):e000905. PubMed ID: 31245051
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
[TBL] [Abstract][Full Text] [Related]
15. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
16. [Cortisone-free rheumatology-Vasculitides].
Holle JU; Moosig F
Z Rheumatol; 2021 May; 80(4):314-321. PubMed ID: 33709164
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
18. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
Terrier B; Jayne DRW; Hellmich B; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Akuthota P; Khoury P; Baylis L; Wechsler ME;
ACR Open Rheumatol; 2023 Jul; 5(7):354-363. PubMed ID: 37312233
[TBL] [Abstract][Full Text] [Related]
19. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
[TBL] [Abstract][Full Text] [Related]
20. Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis.
Masumoto N; Oshikata C; Nakadegawa R; Motobayashi Y; Osada R; Manabe S; Kaneko T; Tsurikisawa N
Allergy Asthma Clin Immunol; 2023 May; 19(1):40. PubMed ID: 37179316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]